In this editorial Rupert Payne, Consultant Editor, celebrates the NHS reaching the milestone of its 70th birthday and reflects on the lessons learnt and what still needs to be done to ensure its continued survival.
Articles: 29.07 July 2018
The Association of the British Pharmaceutical Industry (ABPI) annual conference was held in London in April, in the 70th anniversary year it shares with the NHS. Joy Ogden reports on some of the highlights of the conference, which focused on the future of UK life sciences over the next 70 years
Awareness of the risk factors for venous thromboembolic (VTE) disease and timely administration of thromboprophylaxis can prevent many VTE events. This article examines these risk factors and the recommended strategies to prevent VTE, as well as discussing the diagnosis and treatment of an event that has already occurred
NICE published a new guideline on the assessment and management of heavy menstrual bleeding (NG88) in March, in response to new developments in diagnosis and treatment. This article provides a brief summary of the guidance
The shingles vaccine has been part of the vaccination schedule in the UK since September 2013. It is available for adults aged over 70 years who meet the eligibility criteria. But the programme has not been without its teething problems: this article gives an overview of the evolving shingles vaccination programme and how it is making itself fit for the future
Systemic sclerosis (SSc) is a rare but potentially life-threatening rheumatological condition with a wide range of signs and symptoms. This article describes the GP’s key role in the early diagnosis of SSc and discusses the current and emerging treatment options.
The problem of falsified medicines entering the supply chain has grown in recent years, including in the UK. However, new initiatives such as the EU Falsified Medicines Directive are attempting to confront the issue
Bruton’s tyrosine kinase (BTK) is emerging as a promising target in the treatment of B-cell malignancies. This article discusses the properties of the first licensed BTK inhibitor, ibrutinib (Imbruvica) and its place in the management of mantle cell lymphoma, chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia